[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-ischemic-stroke":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,85,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100647555","phase-2-cc-101-fka-nr1-neural-stem-cell-transplantation-for-adults-with-chronic-ischemic-stroke-100647555",false,"NCT07709845","CC-101 (f\u002Fk\u002Fa NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke","A Phase 2b, Prospective, Randomized, Multi-Center, Double-Blinded, Controlled Trial to Assess the Efficacy and Safety of Stereotactic Intracerebral Transplantation of Allogeneic Neural Stem Cells CC-101 (f\u002Fk\u002Fa NR1) in Adults With Chronic Ischemic Subcortical ± Cortical Stroke","suNR1se II","KEY INCLUSION CRITERIA:\n\n1. Confirmed diagnosis of completed ischemic subcortical stroke in the middle cerebral artery (MCA) distribution with or without cortical involvement based on magnetic resonance imaging (MRI) and\u002For computed tomography (CT) scan(s).\n2. Index stroke occurred ≥ 6 months and ≤ 84 months prior to providing informed consent.\n3. Age ≥ 18 years and ≤ 75 years at the time of providing informed consent.\n4. Chronic motor neurological deficit due to the index stroke.\n5. Total Fugl-Meyer Motor Scale (FMMS) \\> 25 and ≤ 75 at baseline.\n6. Modified Rankin Score (mRS) of 2-4 at baseline.\n7. Subjects taking oral anti-spasticity agent (such as tizanidine hydrochloride or baclofen) must be on a stable dose for 90 days prior to a Screening\u002FBaseline visit.\n\nKEY EXCLUSION CRITERIA:\n\n1. Stroke lesion \\\u003C1 cm3 or \\>100 cm3 as measured by MRI.\n2. Previous history of symptomatic stroke(s) with incomplete motor recovery (NOT including index stroke).\n3. Complete or near complete lack of right and\u002For left upper extremity and\u002For right and\u002For left lower extremity movement as defined by the MRC Scale for Muscle Strength scores.\n4. History of any neuromuscular, rheumatologic, autoimmune, orthopedic, or other disease or condition that limits motor function.\n5. Acute myocardial infarction (heart attack), acute pulmonary embolism (blood clot to the lungs), acute proximal deep vein thrombosis (blood clot in the leg or arm), acute peripheral arterial occlusion, or any other type of acute blood clotting episode within six (6) months of study screening.\n6. Intracoronary and\u002For other intra-arterial stent placement within 12 months of study Screening\u002FBaseline visits requiring uninterrupted anticoagulant and\u002For anti-platelet therapy.\n7. Contracture involving a shoulder, elbow, wrist, finger, hip, knee, and\u002For ankle.\n8. Any contraindication to stereotactic brain surgery.\n9. Presence of serum anti-Human Leukocyte Antigen (HLA) Class I and\u002For Class II antibodies to donor NR1 cells with a Luminex assay value greater than the larger of the central lab's reference ULN or 3,000 Maximum Fluorescence Intensity.","ALL","18 Years","75 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The suNR1se II Study is a Phase 2b randomized, controlled, multi-center clinical trial evaluating the efficacy and safety of stereotactic intracerebral administration of CC-101 (f\u002Fk\u002Fa NR1), an investigational allogeneic neural stem cell therapy, in adults with chronic ischemic stroke and persistent motor impairment. The study is designed to assess whether administration of CC-101 immediately adjacent to the region of prior stroke injury may improve motor function recovery compared with a sham surgical control procedure. The study will also evaluate the role of short-term anti-rejection therapy with tacrolimus in subjects receiving CC-101. Approximately 36 participants will be randomized in a 1:1:1 ration to receive CC-101 plus tacrolimus, sham surgery (no CC-101) plus tacrolimus-matched placebo, or CC-101 plus tacrolimus-matched placebo. Participants will be followed for safety and functional outcomes for at least 12 months following the study procedure.",[28],"Chronic Ischemic Stroke",[30,31,32,33,34,35,36,37,38,39,40,41,42],"Ischemic Stroke","Neural Stem Cells","Stroke","Allogeneic Cell Therapy","Stroke Rehabilitation","Neuroregeneration","Intracerebral Transplantation","Motor Recovery","Chronic Stroke","Stroke Impairment","Stroke Mobility Impairment","Regenerative Medicine","Cell Therapy","NOT_YET_RECRUITING","2026-07-12",{"date":46,"type":47},"2026-07-17","ACTUAL",{"date":49,"type":22},"2027-01",{"date":51,"type":22},"2029-01",{"name":53,"class":54},"Clarion Cells, Inc.","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100617445","phase-1-a-study-of-asp2246-for-people-who-have-movement-problems-caused-by-brain-injury-after-a-stroke-100617445","NCT07318714","A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke","A Phase 1\u002F2 Multicenter, Open-label, Dose Escalation Study Followed by a Randomized, Double-blind Sham-controlled Dose Expansion Study to Evaluate the Safety, Tolerability and Efficacy of ASP2246 in Adult Participants Who Have Motor Dysfunction Associated With Late Subacute to Chronic Ischemic Stroke Due to Supratentorial Perforator Area Infarction","Inclusion Criteria:\n\n* Participant should have had an ischemic cerebral infarction at least 3 months, but not more than 12 months, before signing informed consent. This stroke must be the first-ever stroke for the participant.\n* Participant has current neuromotor dysfunction with a modified Rankin Scale (mRS) score between 2 to 4 at screening.\n* Participant has Fugl-Meyer Assessment (FMA)- upper extremity (UE) score ≥ 20 to ≤ 50 and FMA-lower extremity (LE) score \\\u003C 21 at screening.\n* Participant has supratentorial perforator area infarction (single lacunar infarction or branch-atheromatous disease \\[BAD\\]), as assessed clinically and by magnetic resonance imaging (MRI) at screening.\n* Participant has completed recovery phase rehabilitation after cerebral infarction and spontaneous improvement is not expected during the study period.\n* Participant is willing and physically able to participate in the designated rehabilitation therapy during the study period.\n* Female participant is not pregnant and at least 1 of the following conditions apply:\n\n  * Not a woma(e)n of childbearing potential (WOCBP)\n  * WOCBP who has a negative urine or serum pregnancy test at screening (Unique to Japan: with a medical interview) and agrees to follow contraceptive guidance from the time of giving informed consent to at least 180 days after surgery.\n* Female participant must not be breastfeeding or lactating starting at screening and for 180 days after surgery.\n* Female participant must not donate ova after undergoing surgery and for 180 days after surgery.\n* Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) for a minimum of 180 days after surgery.\n* Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for a minimum of 180 days after surgery.\n* Male participant must not donate sperm for a minimum of 180 days after surgery.\n* Participant agrees not to participate in another interventional study (including rehabilitation) while receiving study intervention\u002Fparticipating for up to 52 weeks in the present study.\n* Participant agrees that the use of antiplatelet, oral anticoagulant or nonsteroidal anti-inflammatory drugs (NSAIDs) will be determined by the local medical staff in accordance with the American College of Chest Physicians Clinical Pharmacy 2022 Guidelines and the Japanese Guidelines for the Management of Stroke 2021. The Japanese guidelines specify that no antiplatelet, oral anticoagulant or NSAIDs are to be restarted post-surgery until results of the day 1 head MRI or computerized tomography (CT) are reviewed and restarting medication is deemed safe.\n\nExclusion Criteria:\n\n* Participant has a cerebral infarct volume \\> 3.4 cm\\^3 or \\\u003C 0.37 cm\\^3, as measured by MRI (use of either a central or local reading is acceptable).\n* Participant has a primary intracerebral or intracranial hemorrhage.\n* Participant has a history of central nervous system (CNS) malignancy or a known presence of any malignancy, unless in remission for \\> 5 years. Exception: The participant with basal or squamous cell skin cancer that has been successfully treated will be considered eligible even if they have been in remission for \\\u003C 5 years.\n* Participant had motor dysfunction of mRS \\> 2 before the onset of the stroke (premorbid mRS).\n* Participant has a history of seizures.\n* Participant has apparent contractures impeding joint movement at shoulder, elbow, forearm, wrist, hand, hip, knee or ankle.\n* Participant with spasticity of grade 2 or higher on the modified Ashworth Scale.\n* Participant has any other neurologic, neuromuscular or orthopedic disease that limits motor function.\n* Participant has an active infection.\n* Participant has a history of or current diagnosis of immunodeficiency.\n* Participant has been deemed to have a high risk of recurrent stroke during the study period (e.g., a family history strongly suggestive of hereditary cerebrovascular disease, such as moyamoya disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy).\n* Participant has an uncontrolled systemic illness, including, but not limited to, hypertension (systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 95 mmHg), resistant hypertension (systolic blood pressure \\[BP\\] ≥ 140 mmHg or diastolic BP ≥ 90 mmHg in a participant who is taking 3 or more medications for hypertension), bleeding disorders, hypercoagulability, diabetes, renal, hepatic or cardiac failure, morbid obesity, or uncontrolled sleep apnea.\n* Participant has any positive findings on tests for occult malignancy, unless a nonmalignant etiology is confirmed.\n* Participant has an uncontrolled major psychiatric illness, including depression (Hamilton Score of \\> 14).\n* Participant has a presence of craniectomy (without bone flap replacement) or other contraindication for stereotactic surgery.\n* Participant has signs and symptoms of intracranial herniation or increased intracranial pressure.\n* Participant with a history of, or electrocardiogram (ECG) evidence suggestive of, recent myocardial infarction (within 6 months of surgery), major dysrhythmia, atrial fibrillation or congestive heart failure.\n* Participant has a substance-related and addictive disorders as defined by the Diagnostic and Statistical Manual of Mental Disorders-5 criteria, including drug or alcohol use.\n* Participant has contraindications to MRI or MRI contrast agent(s).\n* Participant has Montreal Cognitive Assessment (MoCA) score \\\u003C 26.\n* Participant has a history of suicide attempt(s), suicidal behavior, or suicidal ideation (indicated by a 'yes' response to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale \\[C-SSRS\\]) within 12 months prior to study enrollment, or who is assessed at screening to be at a significant risk of committing suicide.\n* Participant has a history of using warfarin or direct oral anticoagulant (DOAC). Exception: The participant will be considered eligible if the medication was discontinued at least 6 months prior to study enrollment, and the embolic source has resolved without recurrence.\n* Participant has a history of neuroleptic drug use. Exception: The participant will be considered eligible if they are neuroleptic medication-free for at least 6 months and their psychiatric symptoms remain mild, stable and do not meet the exclusion criteria.\n* Participant has a history of antiepileptic drug use for seizures. Note: For the participant who has used or is using antiepileptic medications for conditions other than seizures, a detailed risk assessment needs to be conducted to determine eligibility.\n* Participant has had botulinum toxin injection, phenol injection, intrathecal baclofen, or any other interventional treatments for spasticity (except bracing and splinting) within the previous 3 months.\n* Participant has present or previous history of participation in a study with ASP2246.\n* Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.\n* Participant has inadequate organ function as indicated by the laboratory values at screening.\n* Participant has any condition that makes the participant unsuitable for study participation.\n* Participant has known or suspected hypersensitivity to ASP2246 or any components of the formulation used.","80 Years",{"count":64,"type":22},84,[66,25],"PHASE1","This study is for adults who have difficulty moving a few months after a stroke. In this study, ASP2246 will be given to people for the first time. This is known as a \"first in human\" study.\n\nThe main aims of the study are to check the safety of ASP2246, how well people tolerate it, and to find suitable doses of ASP2246 to use later in this study and in future studies.\n\nThis study has 2 parts. In Part 1, people will have brain surgery. During the surgery, different small groups of people will receive a lower to a higher dose of ASP2246. Each dose will be given slowly through a special tube to the damaged part of the brain (intracerebral parenchymal infusion). Any medical problems will be recorded at each dose. This is done to find suitable doses to use in Part 2 of the study.\n\nIn Part 2, other different groups of people will undergo the same type of brain surgery. Some people will receive a higher dose of ASP2246, and some people will receive a lower dose of ASP2246. These are the doses from Part 1. Also, another group of people won't be given ASP2246 during brain surgery. This is known as a sham procedure. This is done so neither the people taking part in Part 2, nor the study doctors (apart from the surgeons) know who will be given ASP2246.\n\nAfter brain surgery, people will be observed for about 2 weeks. For people in Part 1, this will take place in the hospital. For people in Part 2, the observation in hospital may be longer or shorter, depending on the results from Part 1. People in both Parts 1 and 2 will have physical therapy for 12 weeks after surgery and continue to have safety checks for about 1 year after their brain surgery.",[28],[70,71,72,73],"Safety","Tolerability","Efficacy","ASP2246","RECRUITING","2026-07-08",{"date":77,"type":47},"2026-07-09",{"date":79,"type":47},"2026-04-03",{"date":81,"type":22},"2030-02-28",{"name":83,"class":54},"Astellas Pharma Inc",5,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100492631","vagal-nerve-stimulation-in-enhanced-stroke-recovery-the-valor-registry-100492631","NCT05694663","Vagal Nerve Stimulation in Enhanced Stroke Recovery: The VALOR Registry","VALOR","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all procedures in the VNS-Enhanced Stroke Recovery Program\n* Aged 18 or older\n* History of ischemic stroke\n* Upper extremity weakness\n* Planned to undergo VNS implantation\n\nExclusion Criteria:\n\n* Unfavorable candidacy for device implant surgery (e.g., history of adverse reactions to anesthetics, poor surgical candidate in surgeon's opinion, prior injury to the vagus nerve etc.).\n* Medical or mental instability (diagnosis of personality disorder, psychosis, or substance abuse) that would prevent the subject from meeting protocol timeline.",{"count":93,"type":22},40,"1 Year","OBSERVATIONAL","Vagal Nerve Stimulation is a novel proven therapy for patients with chronic ischemic stroke. The primary objective of this registry is to assess the safety of vagal nerve stimulation for stroke recovery through monitoring the occurrence of serious adverse events associated with the surgical procedure or subsequent paired rehabilitation protocol. This registry will monitor patients undergoing VNS for stroke recovery in the Mount Sinai Health System and collect clinical and procedural details, objective outcomes, and patient-reported outcomes associated with vagal nerve stimulation for stroke recovery.",[28],"2026-05-05",{"date":100,"type":47},"2026-05-08",{"date":102,"type":47},"2024-10-09",{"date":104,"type":22},"2028-02",{"name":106,"class":107},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":108},"100602564","effect-of-task-specific-training-with-and-without-biofeedback-on-balance-and-risk-of-falls-in-chronic-ischemic-stroke-patients-of-central-lahore-pakistan-100602564","NCT07125157","Effect Of Task-Specific Training With And Without Biofeedback On Balance And Risk Of Falls In Chronic Ischemic Stroke Patients Of Central Lahore, Pakistan","Effect Of Task-Specific Training With And Without Biofeedback On Balance And Risk Of Falls In Chronic Ischemic Stroke Patients Of Central Lahore, Pakistan, A Randomized Controlled Trial","TST-BIO-STROKE","Inclusion Criteria:\n\nChronic ischemic stroke patients (more than 3 months after stroke) Both Male and Female Patients Patients of 40 or above years of age Patients with Burnstorm stage 3 or above.) Patients with good cognitive function (score of 20 or more on MMSE) Patients who can ambulate 10 m (with or without the assistive device)\n\nExclusion Criteria:\n\nPatients undergoing concurrent therapy or treatment that could influence the effectiveness of this study will be excluded from participation Patients presenting with contraindications to rehabilitation, such as severe uncontrolled hypertension, uncontrolled diabetes, or unstable angina, will be excluded from the study.\n\nIndividuals with prior neurological impairments apart from stroke.","40 Years",{"count":119,"type":22},66,[121],"NA","This randomized controlled trial aims to evaluate the effects of task-specific training with and without biofeedback compared to conventional physical therapy on balance and fall risk in chronic ischemic stroke patients in Lahore, Pakistan. Sixty-six participants will be randomly allocated into three groups: Group 1 (task-specific training with biofeedback), Group 2 (task-specific training without biofeedback), and Group 3 (conventional physical therapy). The intervention will span 12 weeks, consisting of 36 sessions. Key outcome measures include the Berg Balance Scale, Timed Up and Go Test, and the Barthel Index. Assessments will be conducted at baseline, post-intervention, and three-month follow-up. The study hypothesizes that the use of biofeedback in task-specific training will produce significantly greater improvements in balance and reduced fall risk compared to conventional rehabilitation strategies. The study is being conducted at Shadman Medical Center in Lahore and is part of a PhD project from Lincoln University College.",[28,124,125],"Balance Impairment","Risk of Fall",[127,128,129,130,131,132,133],"stroke rehabilitation","biofeedback","task specific training","balance training","fall prevention","berg balance scale","time up and go","2026-02-17",{"date":136,"type":47},"2026-02-19",{"date":138,"type":22},"2026-02-10",{"date":140,"type":22},"2026-03-12",{"name":142,"class":107},"Syed Ali Behram Subazwari"]